Pro Share Advisors LLC Veracyte, Inc. Transaction History

Pro Share Advisors LLC

$36.7 Billion
Q1 2024

A detailed history of Pro Share Advisors LLC transactions in Veracyte, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 18,342 shares of VCYT stock, worth $394,903. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,342

Previous 16,717 9.72%

Holding current value

$394,903

Previous $459,000 11.55%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$21.0 - $29.1 $34,125 - $47,287	1,625 Added 9.72%	18,342 $406,000
Q4 2023 Feb 14, 2024	BUY	$19.72 - $28.68 $49,398 - $71,843	2,505 Added 17.63%	16,717 $459,000
Q3 2023 Nov 13, 2023	BUY	$22.33 - $29.92 $1,295 - $1,735	58 Added 0.41%	14,212 $317,000
Q2 2023 Aug 10, 2023	SELL	$20.96 - $26.99 $1,027 - $1,322	-49 Reduced 0.34%	14,154 $360,000
Q1 2023 May 11, 2023	SELL	$20.58 - $27.89 $19,592 - $26,551	-952 Reduced 6.28%	14,203 $316,000

Q4 2022 Feb 02, 2023	BUY	$15.31 - $29.94 $18,892 - $36,945	1,234 Added 8.86%	15,155 $359,000
Q3 2022 Nov 04, 2022	BUY	$16.58 - $27.9 $5,090 - $8,565	307 Added 2.26%	13,921 $231,000
Q2 2022 Aug 01, 2022	SELL	$15.45 - $29.52 $98,988 - $189,134	-6,407 Reduced 32.0%	13,614 $270,000
Q1 2022 May 10, 2022	SELL	$21.94 - $42.51 $103,337 - $200,222	-4,710 Reduced 19.04%	20,021 $552,000
Q4 2021 Feb 08, 2022	BUY	$36.09 - $53.79 $34,105 - $50,831	945 Added 3.97%	24,731 $1.02 Million
Q3 2021 Nov 12, 2021	SELL	$35.62 - $52.97 $206,667 - $307,331	-5,802 Reduced 19.61%	23,786 $1.11 Million
Q2 2021 Aug 13, 2021	BUY	$32.94 - $56.62 $86,072 - $147,948	2,613 Added 9.69%	29,588 $1.18 Million
Q1 2021 May 14, 2021	BUY	$44.47 - $81.38 $237,914 - $435,383	5,350 Added 24.74%	26,975 $1.45 Million
Q4 2020 Feb 09, 2021	BUY	$32.49 - $61.88 $178,207 - $339,411	5,485 Added 33.98%	21,625 $1.06 Million
Q3 2020 Nov 13, 2020	BUY	$26.73 - $35.67 $36,005 - $48,047	1,347 Added 9.11%	16,140 $524,000
Q2 2020 Aug 03, 2020	BUY	$19.49 - $28.11 $103,433 - $149,179	5,307 Added 55.95%	14,793 $383,000
Q1 2020 May 15, 2020	SELL	$16.13 - $30.17 $120,507 - $225,400	-7,471 Reduced 44.06%	9,486 $231,000
Q4 2019 Feb 12, 2020	SELL	$20.78 - $29.99 $31,855 - $45,974	-1,533 Reduced 8.29%	16,957 $473,000
Q3 2019 Nov 12, 2019	BUY	$23.87 - $30.93 $41,438 - $53,694	1,736 Added 10.36%	18,490 $444,000
Q2 2019 Aug 13, 2019	SELL	$22.1 - $28.56 $6,320 - $8,168	-286 Reduced 1.68%	16,754 $478,000
Q1 2019 May 15, 2019	BUY	$12.0 - $25.76 $3,492 - $7,496	291 Added 1.74%	17,040 $426,000
Q4 2018 Feb 14, 2019	SELL	$9.15 - $14.85 $25,592 - $41,535	-2,797 Reduced 14.31%	16,749 $211,000
Q3 2018 Nov 14, 2018	BUY	$9.55 - $12.64 $18,402 - $24,357	1,927 Added 10.94%	19,546 $187,000
Q2 2018 Aug 13, 2018	SELL	$5.39 - $9.66 $6,812 - $12,210	-1,264 Reduced 6.69%	17,619 $165,000
Q1 2018 May 14, 2018	SELL	$5.44 - $6.97 $16,162 - $20,707	-2,971 Reduced 13.59%	18,883 $105,000
Q4 2017 Feb 14, 2018	BUY	$6.05 - $9.37 $132,216 - $204,771	21,854	21,854 $143,000

Others Institutions Holding VCYT

# of Institutions

257

Shares Held

81.7M

Call Options Held

43K

Put Options Held

82K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $1.54B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Veracyte, Inc. Transaction History